Upcoming Events and Webinars

Shalini-Verma-PierianDx

Shalini Verma
Medical Director, PierianDx

Cancer Genomics Consortium

Join us August 5-8 in Nashville TN at the annual Cancer Genomics Consortium (CGC) conference. We will be on hand to answer your questions and provide best practices for your precision oncology program.

  • Visit out booth.
  • Attend our workshop on August 5. Shalini Verma, MD, PhD, will present "A Practice-Based Guide to Interpretation and Reporting of Sequence Variants in Cancer." 

For more information about the conference, and to register, visit the CGC Annual Meeting Site.

Rakesh-Nagarajan-PierianDx

Rakesh Nagarajan
Founder, PierianDx

Next Generation Dx Summit

Join us in Washington DC August 20-24 as we attend the annual Next Generation DX Summit. We will be on hand to discuss your precision medicine program and how we can help you.

  • Visit us in Booth 404.
  • Attend a panel discussion on August 23 at 11:20 AM local time, led by PierianDx founder Rakesh Nagarajan, MD, PhD: "Disruptive Technologies in Lab Medicine."
amp


Association for Molecular Pathology (AMP) Annual Meeting

Join us at the Association for Molecular Pathology (AMP) Annual Meeting and Expo, November 1-3 in San Antonio, TX. 

  • Visit us in Booth 800.
  • Attend our workshops on October 31 (check back for times).
  • Attend one of our in-booth demonstrations (check back for times).

 

Past Webinars

Shalini-Verma-PierianDx

Shalini Verma, MD, FCAP
Medical Director

Andy-Bredemeyer-PierianDx

Andy Bredemeyer, PhD
VP Products

A Practice-based Guide to Interpretation and Reporting of Sequence Variants in Cancer

Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. Guidelines developed by the Association for Molecular Pathology (AMP) with representation from key institutions, including ACMG, outline a system to categorize sequence variations in cancer. 

Join us for a webinar on July 19 at 12:00 PM Eastern Time as Shalini Verma, MD, FCAP and Andy Bredemeyer, PhD, both from PierianDx, discuss the recent guidelines and apply them to real-life examples. 

In this webinar you will learn:

  • Guidelines for interpretation and reporting
  • What public databases are available, their limitations, and how data from each are compiled. 
  • More about the process for identifying and annotating variants and proposed guidelines for evidence-based classification of somatic variants.

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Dr. Eric Loo

Dr. Eric Loo
Assistant Professor, Dartmouth-Hitchcock

Bringing NGS Testing In-House

May 2, 7:00-7:50 AM

Is insourcing NGS testing worth it?

Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.

In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.

How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?

Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.

In this webinar you will learn:

  • How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
  • How to make a strong business case for in-house NGS testing.
  • Challenges your institution is likely to face by insourcing.
  • Blueprints for overcoming these challenges, including reimbursement.

View Recording

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

PierianDx Hosts Expert Customer Panel Discussion Regarding Debated CMS National Coverage Decision on NGS Testing

February 22, 2018

PierianDx CEO, Dr. Rakesh Nagarajan, and Medical Director, Dr. Shalini Verma, recently posted their perspectives on the CMS website (See Comments). On February 22 at 2 pm CST, Dr. Nagarajan and Dr. Verma will facilitate a roundtable discussion among representatives from NorthShore University Health System, Moffitt Cancer Center, UVA Health System, the Medical College of Georgia at Augusta University, and the University of Vermont Health System.

The panel discussion will focus on how the proposal to limit the coverage to only FDA approved NGS tests with companion diagnostic indications could impose restrictive criteria for coverage with development, making explicit a policy of non-coverage for NGS tests if the test does not meet criteria listed in the proposed NCD. For academic centers, leading cancer institutions, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.

Featuring Speakers from:

  • Ravindra Kolhe, MD, PhD, Director, Georgia Esoteric & Molecular Laboratory at Augusta University
  • Karen L. Kaul, MD, PhD, Chairman of the Department of Pathology, NorthShore University Health System
  • Theresa Ann Boyle, MD, PhD, Molecular Genetic Pathologist at Moffitt Cancer Center
  • Mani S. Mahadevan, M.D., Professor of Pathology Medical Director of Molecular Diagnostics Laboratory at UVA Health System
  • Nikoletta Sidiropoulos, M.D., Director of the University of Vermont Health System Genomics Medicine Laboratory

 

Watch Recorded Webinar

Precision Oncology Roundtable: Ask the Experts about NGS-based Tumor Profiling

October 12, 2017

Featuring Speakers from:

Dartmouth-Hitchcock
Augusta University
Moffitt Cancer Center

This webinar was an interactive roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.

Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — will specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.

The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.

Our panelists will discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Clinical Genomicist Workspace (CGW): Accelerate Your NGS Testing with an End-to-End Integrated Workspace

September 28, 2017

PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out. Nagarajan will discuss:

  • An overview of CGW key features and functions
  • How PierianDx’s knowledgebase helps to deliver clinically actionable results by leveraging millions of biomedical findings across multiple databases to analyze and classify each detected variant
  • Examples of actionable clinical reports, both somatic and constitutional
  • Customer case studies and how CGW has accelerated NGS testing programs, streamlined lab efficiencies and ultimately improved patient care

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Building a Best-in-Class Precision Medicine Program: The Moffitt Cancer Center Story

September 14, 2017

Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.
Dr. Magliocco will discuss:

  • Key variables that played an important part in Moffitt Cancer Center’s evolution.
  • The role of the state-of-the-art Morsani Molecular Diagnostics Laboratory played in that evolution
  • Pathways to success, unexpected barriers, and an in-depth review of what steps were taken to ensure that the patient comes first
  • A blueprint for other clinical labs seeking to accelerate precision medicine and NGS testing

Watch Recorded Webinar

Dr. Rakesh Nagarajan

Dr. Rakesh Nagarajan
CEO, PierianDx

Taking Your NGS Testing Program to the Next Level with Enhanced Validation and Interpretation Services

July 13, 2017 at 11:00am CST

The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput. Specifically, Nagarajan will discuss:

  • Guidelines for improved test validation covering a range of examples
  • Various validation reports, covering a range of different assays
  • Understanding the different roles of automated interpretation and clinical interpretation utilizing genomic scientists and medical directors
  • Case studies of customers who have enhanced their clinical lab capability with PierianDx validation and interpretation services

Watch Recorded Webinar

Dr. Nikoletta Sidiropoulos

Dr. Nikoletta Sidiropoulos

Accelerating Your NGS Testing Program: Examples and Case Studies

On March 9th, Clinical Genomicist Workspace user and Partner Sharing Network contributor, Dr. Nikoletta Sidiropoulos from University of Vermont Medical Center hosted a webinar with PierianDx exploring various ways clinical labs have established or expanded their NGS testing programs by implementing improved workflow and clinical integration into their organization. Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.

Watch Recorded Webinar

NGS Roundtable: Ask the Experts about the Future of Clinical NGS Testing

This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.

Topics covered by the expert panel include the importance of proficiency testing, both from the regulatory and quality perspective, and technical and clinical advances in using NGS to predict effective immunotherapy and determine tumor mutation load.

Watch Recorded Webinar

Recent News

A Guide for the Interpretation and Reporting of Sequence Variants in Cancer

A Guide for the Interpretation and Reporting of Sequence Variants in Cancer

August 14, 2018
Recently we hosted a webinar in which Medical Director, Shalini Verma, and VP Product, Andy Bredemeyer, reviewed and applied the Association for Molecular Pathology (AMP) joint consensus guidelines for the interpretation and reporting of sequence
Read More
We Know Precision Medicine: Andy Bredemeyer, VP Product

We Know Precision Medicine: Andy Bredemeyer, VP Product

July 26, 2018
"We Know Precision Medicine" is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this article, Andy Bredemeyer, VP Product, discusses how
Read More
Less Variation, More Standardization in Somatic Variant Interpretation and Reporting

Less Variation, More Standardization in Somatic Variant Interpretation and Reporting

July 13, 2018
Preparing for our upcoming webinar -- A Practice-based Guide for Interpretation and Reporting of Sequence Variants in Cancer--caused us to think about the evolution of next generation sequencing (NGS) into the clinic and how there’s hasn't been a
Read More
We Know Precision Medicine: Rakesh Nagarajan

We Know Precision Medicine: Rakesh Nagarajan

June 27, 2018
"We Know Precision Medicine" is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this first article, Rakesh Nagarajan, Founder and Executive
Read More
PierianDx Expands to Australia with Addition of Anatomical Pathology PathWest Laboratory Medicine

PierianDx Expands to Australia with Addition of Anatomical Pathology PathWest Laboratory Medicine

June 11, 2018
PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that the Department of Anatomical Pathology PathWest Laboratory Medicine will use the company’s Clinical Genomics WorkSpace™ (CGW) platform,
Read More